protein

Recombinant Human Estrogen Receptor Binding Site Associated Antigen 9

MBS143738

0.01 mg

140 USD

Recombinant Protein

Recombinant Human Estrogen Receptor Binding Site Associated Antigen 9

Estrogen Receptor Binding Site Associated Antigen 9

EBAG9 Human; Estrogen Receptor Binding Site Associated Antigen 9 Human Recombinant; EB9; PDAF; RCAS1; EBAG9; Receptor-binding cancer antigen expressed on SiSo cells; Cancer-associated surface antigen RCAS1; Estrogen receptor-binding fragment-associated gene 9 protein

receptor-binding cancer antigen expressed on SiSo cells; Receptor-binding cancer antigen expressed on SiSo cells; receptor-binding cancer antigen expressed on SiSo cells; cancer-associated surface antigen RCAS1; estrogen receptor-binding fragment-associated gene 9 protein; estrogen receptor binding site associated, antigen, 9; Cancer-associated surface antigen RCAS1; Estrogen receptor-binding fragment-associated gene 9 protein

EBAG9

EBAG9; EBAG9; EB9; PDAF; RCAS1

RCAS1_HUMAN

E Coli

213

Greater than 90% as determined by SDS-PAGE.

The EBAG9 protein solution contains 20mM Tris-HCl pH-8, 1mM DTT, 2mM EDTA and 10% glycerol. Sterile Filtered colorless solution.

RECOMBINANT & NATURAL PROTEINS; Recombinant Proteins

Description: EBAG9 Human Recombinant produced in E Coli is a single, non-glycosylated polypeptide chain containing 207 amino acids (28-213) and having a molecular mass of 23.4 kDa. The EBAG9 protein is fused to a 20 amino acid His-Tag at N-terminus and purified by standard chromatography techniques. Introduction: EBAG9 is a type III transmembrane protein that is primarily located in the Golgi. EBAG9 is a tumor-associated antigen that is expressed at high frequency in a variety of cancers, such as advanced breast and prostate cancers. while the EBAG9 acts to inhibit the growth of receptor-binding cells and induced apoptosis of immune cells, cancer cells may evade immune surveillance. Thus immunodetection of EBAG9 expression can be a negative prognostic indicator. EBAG9 promotes progression of bladder cancer. In rheumatoid arthritis, the deficiency of EBAG9 induces CTL infiltration through failure to evade immune attack, therefore leading to apoptosis of the synovial lining cells. EBAG9 is involved in controlling exocytosis processes. EBAG9 expression plays a role in the progression of oral squamous cell carcinoma. EBAG9 plays a specific role in premature stages of breast carcinogenesis.

525459422

NP_001265867.1

NM_001278938.1

O00559

29,466 Da

This gene was identified as an estrogen-responsive gene. Regulation of transcription by estrogen is mediated by estrogen receptor, which binds to the estrogen-responsive element found in the 5'-flanking region of this gene. The encoded protein is a tumor-associated antigen that is expressed at high frequency in a variety of cancers. Alternate splicing results in multiple transcript variants. A pseudogene of this gene has been defined on chromosome 10. [provided by RefSeq, Jul 2013]

RCAS1: May participate in suppression of cell proliferation and induces apoptotic cell death through activation of interleukin-1- beta converting enzyme (ICE)-like proteases. Homodimer. By estrogen. Widely expressed. Expressed in ovary, testis, prostate, thymus, muscle and heart, but not in small intestine, colon, lymph nodes, or peripherical blood lymphocytes. The protein is not detected in any of the above organs. Protein type: Membrane protein, integral; Apoptosis. Chromosomal Location of Human Ortholog: 8q23. Cellular Component: Golgi membrane; Golgi apparatus; focal adhesion; integral to membrane; plasma membrane; secretory granule. Molecular Function: apoptotic protease activator activity. Biological Process: apoptosis; regulation of cell growth

0.01 mg

140 USD

0.05 mg

205

1 mg

1790